# Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

> **NCT02211131** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 150 (actual)

## Conditions studied

- Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

## Interventions

- **DRUG:** Talimogene Laherparepvec
- **PROCEDURE:** Immediate surgical resection of melanoma lesion(s)

## Key facts

- **NCT ID:** NCT02211131
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-03
- **Primary completion:** 2019-04-30
- **Final completion:** 2022-04-28
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211131, "Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02211131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*